
The Covid-19 vaccine from Astrazeneca has taken some hits since last week, when the European Medicines Agency (EMA) confirmed that the EMA's safety experts sees a possible connection between this vaccine and a series of rare but highly serious, and sometimes fatal, side effects.
Even though many countries have limited their use of the vaccine, and some – like Denmark – have opted to suspend it immediately, it does not seem like this will have any financial consequences for Astrazeneca. This firm runs all of its global vaccine sales as a non-profit project, and the company is regretful about the fact that people seem to forget this, as criticism is raining down on Astrazeneca in relation to the possible side effects of the vaccine on the one hand, and overdue deliveries on the other.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.